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Background: The objective of our study was to compare the clinical outcomes of idiopathic full-thickness
macular hole surgery using either triamcinolone (TA) or VisCoat treatment of the macular hole before
indocyanine-green (ICG)-assisted internal-limiting-membrane (ILM) peeling.
Methods: During macular hole surgery, the hole and adjacent areas were treated with TA (Group 1, n ¼ 15
eyes) or VisCoat (Group 2, n ¼ 22 eyes) to minimize ICG-induced toxicity during ILM peeling. Changes in
visual acuity and anatomical success rates were compared between the two groups.
Results: At 6 months following surgery, the hole closure rate was 80% (12/15 eyes) in Group 1 and 100%
(22/22 eyes) in Group 2. The mean  standard deviation logarithm of the minimum angle of resolution
decreased from 1.40  0.41 to 1.08  0.38 in Group 1 (p ¼ 0.04) and from 1.25  0.41 to 0.75  0.44 in
Group 2 (p < 0.001), indicating that a greater increase in the average best corrected visual acuity had
occurred in Group 2 than in Group 1 (p ¼ 0.02). At 1 month following surgery, small outer-retinal blebs
were noted in 42% of the closures in Group 1 and 9% of the closures in Group 2. The blebs persisted in
four Group-1 participants for >1 year, but no long-standing outer retinal bleb occurred in Group 2.
Conclusion: Participants who received the VisCoat treatment displayed a higher hole closure rate and
a better ﬁnal visual acuity than those who received the TA treatment. Participants who received the TA
treatment also had more outer retinal blebs at 1 month and 1 year or more following the surgery.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Internal-limiting-membrane (ILM) peeling has become an
integral part of surgical treatments of macular hole and other
vitreoretinal disorders.1e6 Direct removal of the thin ILM is
technically challenging. Many substances have been used to stain or
coat the membrane to facilitate the visualization of the ILM.7e12
Possible retinal toxicity and inadequate staining quality have
been reported for the various substances tested to date. Viscoelastic
material and autoblood have been used to cover the hole before the
advent of indocyanine-green (ICG) staining.13,14 We evaluated the
clinical outcomes of idiopathic full-thickness macular hole surgery
using either triamcinolone (TA) or VisCoat treatment of themacular
hole before ICG-assisted ILM peeling.ology, College of Medicine,
han Road, Taipei, Taiwan.
g).
e Ophthalmologic Society of Taiw2. Methods
The clinical charts of all patients with Stage 2, Stage 3, or Stage 4
idiopathicmacular hole undergoing vitrectomywith ILM peeling by
a single surgeon during February 2007 to March 2010 were
retrospectively reviewed for this study. The Group-1 participants
received ILM peeling using TA treatment before ICG staining, and
the Group-2 participants received VisCoat treatment before ICG
staining. Informed consent was obtained from all the participants.
The study was conducted according to the Declaration of Helsinki
and approved by the ethics committees of our institutions. The age
and sex of the participant, the diagnosis, onset to intervention
interval, duration of the follow-up period, pre- and postoperative
best-corrected visual acuity (BCVA) based on themean logarithm of
the minimum angle of resolution (Log MAR), intraocular pressure
(IOP), and operative complications were recorded for each case.
Fundus photography and optical coherence tomography (OCT)were
performed before surgery and at 1 month, 3 months, and 6 months
or longer following surgery to evaluate the structural changes of thean. Published by Elsevier Taiwan LLC. All rights reserved.
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were also performed following surgery. All participants were
postoperatively followed-up for 6 months or longer.
Either a 20-gauge or a 23-gauge vitrectomy set-up was used for
the surgeries. For TA suspension, a 40 mg Kenacort-A vial
(Genovate, Taipei, Taiwan) was allowed to stand overnight. The
upper 0.8 mL of supernatant was discarded, and the remainder of
the contents were resuspended in an equal amount of balanced salt
solution (BSS) immediately before use. The resuspended TA was
drawn into a 1 mL syringe, and further diluted with BSS to 20 g/L. A
0.17% ICG solution (1.7 g/L) was prepared by diluting 25 mg ICG
(Daiichi Pharmaceutical, Tokyo, Japan) in 15mL of 5% sterile glucose
solution. The 0.17% ICG solutionwas drawn into a 1 mL syringe. The
syringes containing the TA suspension and ICG solution were
equipped with 26-gauge blunt-tipped cannulas.
Following TA-assisted posterior hyaloid removal in the Group-1
participants, diluted TAwas applied directly above the hole to cover
the hole and the surrounding area. Less than 0.1 mL of ICG solution
was slowly applied to the retinawithin the arcade, primarily on the
temporal side. The intravitreal ICG dye was immediately removed
by back-ﬂushing. A small amount of TA was allowed to remain as
a surface coating. A Tano diamond-dusted membrane scraper or
a barbed 25-gauge needle was used to create an ILM break within
the ICG stained area (Fig. 1). The edge of the break was gently lifted
using a 20- or 23-gauge end-grasping conformal vertical forceps.
Maculorrhexis was performed in a circular manner across the
macula. After completion of the ILM peeling, the residual TA par-
ticles on the retinal surface were gently removed by back-ﬂushing.
No attempt was made to forcibly remove all the adherent particles.
The peripheral retina was examined for possible breaks, followed
by aireﬂuid exchange and 15% C3F8 infusion into the vitreous
cavity. For pseudophakic eyes, the infusion line was temporally
closed during the TA and ICG injection. The patients remained in
a prone position for about 1 week.
The VisCoat used was a commercially available mixture of
sodium chondroitin sulfate and sodium hyaluronate (Alcon
Laboratories, Fort Worth, TX, USA). The surgical technique used for
the Group-2 participants was the same as that used for Group 1,
with the VisCoat solution used in place of the TA solution and the
following additional modiﬁcations. The VisCoat solution was
applied to the hole and the adjacent area, and the ICG solution was
applied around the VisCoat-coated area within the arcade (Fig. 2).
The VisCoat was aspirated from the hole following the ILM staining.Fig. 1. Indocyanine-green (ICG) staining following triamcinolone (TA) protection before inte
temporal retina with scattered TA particles coating the posterior pole was observed after the
noted during ILM peeling.To examine the differences in the clinical outcomes between
Group 1 and Group 2, statistical analysis of noncontinuous variables
was performed using the Chi-square test or Fisher’s exact test. The
age, onset to intervention interval, duration of follow-up period,
preoperative and postoperative log MAR BCVA were compared
between the groups using the ManneWhitney U test. The pre- and
postoperative log MAR BCVA in each group were compared using
a paired t test. A p-value <0.05 was considered to represent a sta-
tistically signiﬁcant difference.
3. Results
The demographic data of the participants are shown in Table 1.
No signiﬁcant differences in age, sex, the onset to intervention
interval, or the lens status were observed between Groups 1 and 2.
Among the Group-1 participants, two patients had pseudophakic
eyes before the macular hole surgery, one patient received a com-
bined cataract and macular hole surgery, and four patients received
cataract surgery 4e6months following themacular hole surgery. In
Group 2, four patients were pseudophakic before the macular hole
surgery, seven patients received combined cataract and macular
hole surgery, and one patient received cataract surgery 5 months
following the macular hole surgery. Postoperative transient
elevation of IOP was observed in one case in Group 1. All patients
received postoperative follow-up examinations for at least 6
months.
The primary hole closure rate was 80% (12/15 eyes) in Group 1
and 100% (22/22 eyes) in Group 2. After surgery, the mean BCVA
improved signiﬁcantly in both groups. No signiﬁcant difference in
preoperative BCVA (p ¼ 0.34) was found between the two groups,
but a signiﬁcant difference in postoperative BCVA (p ¼ 0.02) was
observed (Table 2). The visual acuity changes and the clinical
features of all participants are shown in Tables 3 and 4. The OCT
analysis revealed small outer-retinal defects or blebs in 42% (5 eyes)
of Group 1 and 9% (2 eyes) of Group 2 at 1 month following surgery,
with the blebs persisting in four eyes in Group 1 for longer than 1
year (Fig. 3).
4. Discussion
In ICG staining of the ILM, the ICG readily binds to Type-4
collagen ﬁbers, greatly facilitating the visualization and removal
of the membrane. However, the toxicity to the retinal pigmentrnal limiting membrane (ILM) peeling in macular hole surgery. (A) ICG staining of the
excess ICG and TAwere washed out. (B) The highlighting of the ILM by TA particles was
Fig. 2. Indocyanine-green (ICG) staining following VisCoat protection before internal limiting membrane (ILM) peeling in macular hole surgery. (A) ICG staining of the posterior
retina sparing the hole with VisCoat protection and the adjacent area was observed after the excess ICG and VisCoat were washed out. (B) Completion of maculorrhexis with
removal of central ILM was observed.
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of the phototoxicity from the ﬁber optic light precludes the uni-
versal acceptance of ICG staining in ILM removal.15e17 Alternative
materials have been used, such as trypan blue (TB), brilliant blue G
(BBG), and TA suspension. Although the TB and BBG stains may be
less toxic to the retinal tissues, TB has a greater binding afﬁnity to
the preretinal tissue, which may cause nonuniform staining of
ILM.15e18 The BBG stain has demonstrated speciﬁc staining of the
ILM at a concentration of 0.25 g/L without signiﬁcant toxicity.
However, Henrich et al reported signiﬁcantly superior contrast
using ICG staining than that obtained using BBG staining in 26
chromovitrectomy interventions.12,19,20 Among the more recently
developed vital dyes, infracyanine green may exhibit less in vitro
toxicity, but its toxic effects have been reported in cultured retinal-
ganglion cells and human retinal-pigment epithelial cells.21 TA
suspension is easy to prepare and cost effective. However, it re-
mains controversial whether adverse effects may be associated
with the TA particles that remain within the hole following clo-
sure.10,11,22e24
To avoid possible ICG toxicity to the pigment epithelium, we
used VisCoat or TA ﬁrst to ﬁll the macular hole and to coat
the surrounding retinal surface to prevent the diffusion of ICG into
the hole. The ILMwas peeled easily, and the ﬂap was readily visible.
Using this technique, only the local macular area is stained by the
ICG. Thus, the toxicity of ICGmay be reduced, even at relatively high
concentrations. The three substances used for our technique,
VisCoat, TA in BSS, and ICG in 5% glucose, are all slightly denser than
BSS. This property ensures that these liquids will descend to the
bottomof the vitreous cavity, thus providing amore efﬁcientmeans
of coating the target area. This denser coating may also allowTable 1
Baseline clinical characteristics of Group 1 and Group 2.
Group 1a
(n ¼ 15)
Group 2b
(n ¼ 22)
p
Age, mean and range (y)c 65.3  7.4;
49e78
60.8  11.2;
28e77
0.23
Sex (Male/Female) 7/8 8/14 0.73
Onset to intervention
interval (mo)c
3.5  2.8 4.1  3.9 0.98
Lens status (preoperative)
Phakic, n (%) 13 (86.7%) 18 (81.8%) 1.00
Pseudophakic, n (%) 2 (13.3%) 4 (18.2%)
Follow-up duration (mo)c 29.2  11.5 10.0  5.4 <0.001
a Group 1: Triamcinolone-assisted internal membrane peeling.
b Group 2: VisCoat-assisted internal membrane peeling.
c Expressed as the mean  standard deviation.adequate staining at lower ICG concentrations. Saito and Iida used
a similar surgical technique for six cases in which a viscoelastic
material was applied for hole protection before staining with 0.5%
ICG in BSS.13 However, we used 0.17% ICG in a 5% glucose solution
because the use of 0.5% ICG for ILM staining has been associated
with deterioration of the visual ﬁeld up to 3 years following
surgery.17
We observed a higher primary anatomical success rate (80% vs.
100%) and a better visual acuity improvement (ﬁnal log MAR  SD
BCVA 1.08 0.38 vs. 0.75 0.44, p¼ 0.02) in Group 2 than in Group
1. Both the autoﬂuorescence imaging analysis at 1 month following
surgery and the visual ﬁeld examination at 1 year following surgery
in selected cases revealed no residual ICG within the hole or on the
surrounding macula. In this technique, TA coats the surface of the
retina, and could be used to partially replace the ICG for membrane
identiﬁcation. We found that this property allowed the ICG stain to
be used minimally at the area designated for the initiation of the
ILM breakage, which may have contributed to reduced ICG toxicity.
The disadvantage of the use of TAwas that it was difﬁcult to entirely
remove all the TA particles from the hole by backﬂushing without
risking injury to the hole edge. Although TA-assisted ILM peeling
has been widely used by many investigators, other reports have
indicated the toxicity of TA to the retina.10,11,22e24 The potential
risks of residual TA in the macular hole during healing are widely
debated. The mechanical presence of the solid TA and its
antiproliferative properties may hinder hole closure. For these
reasons, we investigated the use of VisCoat for hole protection after
hole closure failed in three cases in Group 1. Because the use of the
VisCoat provided protection without concerns of toxicity to the
retinal-pigment epithelium, a larger area of the retina was stained
to ensure constant visualization of ILM during peeing. In our ICG
application, all or most of the stain could be removed, thus reducing
ICG toxicity to both the retinal-ganglion cells and the retinal-
pigment epithelial cells.
Compared to the ﬁnal log MAR BCVA values in a previous
retrospective study of nonstained ILM peeling and intraocular gasTable 2
Visual acuity levels of preoperative and postoperative outcome between Group 1
and Group 2.
Group 1a Group 2b p
Preoperative logMAR (mean  SD) 1.40  0.41 1.25  0.41 0.34
Postoperative logMAR (mean  SD) 1.08  0.38 0.75  0.44 0.02
p 0.04 <0.001
logMAR ¼ logarithm of the minimum angle of resolution; SD ¼ standard deviation.
a Group 1: Triamcinolone-assisted internal membrane peeling.
b Group 2: VisCoat-assisted internal membrane peeling.
Table 3
Demographic data and clinical outcome in patients receiving indocyanine-green-assisted internal-limiting-membrane peeling following triamcinolone protection (Group 1).
Case no. Sex Age (y) OD/OS Stage of
macular hole
Lens status on
last visit
Preoperative
logMAR BCVA
Postoperative
logMAR BCVA
>6 mo
postoperation
Bleb formation,
1 mo postoperation
Bleb formation,
12 mo postoperation
1 F 69 OS 3 Phakic 0.7 0.4 d
2 M 56 OD 2 Pseudophakic 1.3 1.0 þ þ
3 M 74 OD 3 Pseudophakic 2.0 1.3 d
4 F 65 OD 3 Phakic 1.0 1.0 þ d
5 F 72 OS 3 Pseudophakic 1.6 1.6 X X
6 F 49 OD 4 Phakic 2.0 1.3 d
7 M 78 OS 3 Phakic 1.6 1.3 d
8 M 67 OD 4 Pseudophakic 1.3 0.7 d
9 F 62 OS 3 Phakic 1.3 1.3 X X
10 M 61 OD 3 Pseudophakic 0.7 0.4 þ þ
11 M 68 OS 4 Pseudophakic 1.6 1.3 d
12 F 61 OD 4 Pseudophakic 1.3 0.7 þ þ
13 F 61 OD 4 Phakic 1.3 1.0 d
14 M 72 OS 4 Phakic 2.0 1.6 þ þ
15 F 65 OD 4 Phakic 1.3 1.3 X X
BCVA ¼ best-corrected visual acuity; F ¼ female; logMAR ¼ logarithm of the minimum angle of resolution; M ¼ male; OD ¼ right eye, OS ¼ left eye; X ¼ macular hole
not closed.
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improvement in visual acuity.25 However, our patients had lower
average visual acuity before surgery, as evidenced by higher initial
preoperative log MAR BCVA values (mean, 1.40 and 1.25 vs, 0.9).25
In addition, patients in both groups in our study had highly
progressed cataract formation. Nonetheless, the extent of
improvement in visual acuity in Group 2 (approximately 0.5 log
MAR) was consistent with that of the previous study of nonstained
ILM peeling.25
Small outer retinal defects were detected by OCT in 42% (5 eyes)
of Group 1 and 9% (2 eyes) of Group 2 at 1 month after surgery.
Takayashi and Kishi also reported early postoperative bridge
formation at the fovea in 11 eyes (44%) using OCT at a 1-month
follow-up, and it took an average of 2 months for the bridged tissue
to reattach to the retinal-pigment epithelium.26 Most of the small
outer retinal defects were similar to the bridge formation described
by Takayashi and Kishi (slit-like or bleb-like). In addition, the outerTable 4
Demographic data and clinical outcome in patients receiving indocyanine-green-assisted
Case no. Sex Age (y) OD/OS Stage of
macular hole
Lens status on
last visit
Preoperat
logMAR B
1 M 68 OD 3 Pseudophakic 0.7
2 F 68 OS 4 Pseudophakic 1.6
3 F 69 OS 3 Pseudophakic 1.3
4 M 50 OS 3 Phakic 0.8
5 F 57 OS 3 Phakic 1.0
6 F 52 OD 4 Phakic 2.0
7 F 66 OS 4 Pseudophakic 1.3
8 F 61 OS 3 Phakic 1.3
9 F 28 OD 3 Phakic 1.3
10 F 60 OS 3 Pseudophakic 1.6
11 F 77 OD 4 Phakic 1.6
12 F 74 OS 4 Pseudophakic 1.0
13 F 58 OS 3 Phakic 1.3
14 M 62 OS 3 Pseudophakic 0.5
15 F 64 OS 4 Pseudophakic 1.6
16 M 70 OS 4 Pseudophakic 2.0
17 M 69 OS 4 Pseudophakic 0.7
18 F 72 OS 4 Pseudophakic 1.3
19 F 58 OS 3 Pseudophakic 1.0
20 M 58 OS 3 Phakic 1.6
21 M 54 OD 3 Phakic 0.8
22 M 42 OD 4 Phakic 1.3
BCVA ¼ best-corrected visual acuity; F ¼ female; logMAR ¼ logarithm of the minimumretinal defects persisted for>1 year in four cases in Group 1 (Fig. 3).
We hypothesized that the persistent outer retinal defects may have
been caused by residual TA in the macular hole. Group-1
participants with prolonged blebs displayed diminished visual re-
covery, compared to the participants in Group 2 with retinal de-
fects. Recently developed spectral domain OCT may better
delineate the nature of such blebs and possible disruption of the
outer retinal layers.27e29
The retrospective design of our study and the relatively small
size of our cohort may represent limiting factors to our ﬁndings.We
posited that the inclusion of cases performed by a single surgeon
only in a relatively short period would reduce study bias. However,
the period during which the TA technique was used preceded the
period during which the VisCoat technique was used, and
progressive improvement in surgical expertise speciﬁc to the
macular hole procedure cannot be discounted. Furthermore, in
contrast to the homogeneous VisCoat mixture, the heterogeneousinternal-limiting-membrane peeling following VisCoat protection (Group 2).
ive
CVA
Postoperative
logMAR BCVA,
>6 mo after operation
Bleb formation,
1 mo after operation
Bleb formation,
12 mo after operation
0.5 þ d
1.3 d
0.8 d
0.2 þ d
0.4 d
2.0 d
0.8 d
1.0 d
0.5 d
0.5 d
1.3 d
0.5 d
0.7 d
0.3 d
0.7 d
1.3 d
0.5 d
0.7 d
0 d
1.0 d
0.7 d
0.8 d
angle of resolution; M ¼ male; OD ¼ right eye, OS ¼ left eye.
Fig. 3. Optical coherence tomography (OCT) analysis of eyes before and after macular hole surgery. (A) OCT of the right eye demonstrated a macular hole before surgery. (B) An outer
retinal bleb was seen at 6 months following the surgery. (C) A smaller outer retinal bleb remained detectable for 15 months following surgery.
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ICG solution into the base of the hole, which may have negatively
inﬂuenced the outcomes of Group 1. In addition, approximately half
of the patients did not undergo cataract surgery before the ﬁnal
follow-up examination, which may have confounded our compar-
ison. No signiﬁcant differences in the visual outcomes were
observed between the pseudophakic patients in Group 1 and the
phakic patients in Group 2 (1.00  0.42 vs. 0.86  0.42, p ¼ 0.48).
However, the cataract surgery may have been selectively per-
formed based on the anatomical result in the Group-1 cases (TA
treatment). On the other hand, the visual outcome might be better
if the cataract surgery was done in the VisCoat group.
In summary, we found that, although the use of VisCoat or TA
during ICG-assisted ILM peeling in the treatment of idiopathic
macular hole may avoid ICG toxicity, the VisCoat treatment resulted
in a higher hole closure rate and signiﬁcantly better visual
improvement. Although newly developed vital dyes displaying
lower cell toxicity have been recently reported, VisCoat hole-
protection during ICG staining remains an alternative strategy for
reducing the risk of ICG retinal toxicity.
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